Oxurion NV – Journal of Pharmacokinetics and Pharmacodynamics highlights desirable PK/PD profiles of THR-687 and THR-149 août 16, 20210CommentsEN Read More
Tussentijdse halfjaarresultaten 30 juni 2021 juin 30, 20210CommentsTussentijdse halfjaarresultaten 30 juni 2021 Read More
Interim Financial Report Half-year results as of June 30, 2021 juin 30, 20210CommentsInterim Financial Report Half-year results as of June 30, 2021 Read More
Oxurion NV to Focus Resources on Clinical Assets THR-687 and THR-149 juin 25, 20210CommentsEN Read More
OXURION Confirms Institutional Review Board Approval and Submission of the Investigational New Drug Application to the FDA to Start Phase 2 Study Evaluating THR-687 for Diabetic Macular Edema (DME) juin 10, 20210CommentsEN Read More
OXURION Completes Patient Enrollment for Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME) juin 8, 20210CommentsEN Read More
OXURION NV Presenting Scientific Data at ARVO 2021 Annual Meeting avril 30, 20210CommentsEN Read More
Oxurion NV – Publication in ‘Progress in Retinal and Eye Research’ highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD avril 7, 20210CommentsEN Read More
Oxurion NV enters into a Capital Commitment of up to €30 Million with Negma Group avril 6, 20210CommentsEN Read More
Oxurion NV appoints Prof Alan Stitt as Chief Scientific Officer janvier 20, 20210CommentsEN Read More
Jaarrapport – financiële informatie 2020 décembre 30, 20200CommentsJaarrapport - financiële informatie 2020 Read More
Annual Report – Financial Information 2020 décembre 30, 20200CommentsAnnual Report - Financial Information 2020 Read More
OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent Offices novembre 9, 20200CommentsEN Read More
